Pathology: mNSCLC - L2 - EGFR mutant; mNSCLC - L2 - PDL1 positive;
mNSCLC - L2 - EGFR mutant | mNSCLC - L2 - PDL1 positive | ||
CAURAL (EXPLORATORY), 2019 | ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 | ||
durvalumab alone | 1 | T1 | |
durvalumab plus osimertinib | 1 | T1 | |
Standard of Care (SoC) | 0 | T0 | |
osimertinib | 0 | T0 |